Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 3, 2011, Pages 172-179

  Álvarez, Beatriz ^a   Arcos, Javier ^a   Fernández Guerrero, Manuel L ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

anti CD20 drugs; antitumor necrosis factor drugs; chronic granulomatous disease; infliximab; primary immunodeficiency; tuberculosis; tumor necrosis factor blockers

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; ETANERCEPT; GAMMA INTERFERON; GEMTUZUMAB; GLUCOCORTICOID; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; ITRACONAZOLE; METHOTREXATE; NATALIZUMAB; OZOGAMICIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RILONACEPT; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ASPERGILLUS NIDULANS; BURKHOLDERIA CEPACIA; BURKHOLDERIA GLADIOLI; CHEDIAK HIGASHI SYNDROME; CHRONIC GRANULOMATOUS DISEASE; CINCA SYNDROME; CROHN DISEASE; CYTOMEGALOVIRUS; DISEASE SURVEILLANCE; GRANULOMA; HYPER IGE SYNDROME; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG INFECTION; LYMPHOCYTE DEPLETION; MORBIDITY; MORTALITY; NEOSARTORYA; NONHUMAN; PARAINFLUENZA VIRUS 3; PSEUDOMONAS AERUGINOSA; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS AUREUS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL PRODUCTS; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOMODULATION; LUNG DISEASES; OPPORTUNISTIC INFECTIONS;

EID: 79953906170     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283455c0b     Document Type: Review

References (38)

1. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140:255-266.
2. Movahedi M, Aghamohammadi A, Rezaei N, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol 2004; 134:253-259. (Pubitemid 38813040)
3. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-169.
4. Van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.
5. Martire B, Rondelli R, Soresina A, et al., IPINET. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008; 126:155-164.
6. Jones LB,McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland - a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211-218. (Pubitemid 351520920)
7. Mailman TL, Schmidt MH. Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 2005; 16:245-248. (Pubitemid 41367845)
8. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102-111.
9. Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatr Radiol 2010; 40:657.
10. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010; 38:3-10. In this review, some of the recent developments in infectious syndromes, inflammatory complications and curative approaches in CGD are discussed.
11. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007; 45:673-681. (Pubitemid 47378879)
12. Ameratunga R, Woon ST, Vyas J, Roberts S. Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin Pediatr (Phila) 2010; 49:1143-1146.
13. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S182-S194. This review discusses pathogenesis, diagnosis and treatment of PIDs, with special attention to recent advances in the field.
14. Joshi AY, Iyer VN, Hagan JB, et al. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc 2009; 84:16-22. This cohort study describes the epidemiology and clinical presentations of PIDs and also examines the effects of delayed diagnosis and consequent morbidity.
15. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, et al. Primary immunodefi-ciencies: 2009 update. J Allergy Clin Immunol 2009; 124:1161-1178.
16. Roxo Junior P. Primary immunodeficiency diseases: relevant aspects for pulmonologists. J Bras Pneumol 2009; 35:1008-1017. It is an updated article on the most relevant aspects of PID diseases, especially regarding the clinical manifestations related to the diagnosis with emphasis on the need of early recognition of warning.
17. Wood PM. Primary antibody deficiency syndromes. Curr Opin Hematol 2010; 17:356-361.
18. Bustamante J, Zhang SY, von Bernuth H, et al. From infectious diseases to primary immunodeficiencies. Immunol Allergy Clin North Am 2008; 28:235-258. (Pubitemid 351522415)
19. Bush A. Recurrent respiratory infections. Pediatr Clin North Am 2009; 56:67-100.
20. Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008; 122:1043-1051.
21. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010; 135:255-263.
22. Cutolo M, Seriolo B, Pizzorni C, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008; 8:153-155.
23. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560-1567. (Pubitemid 350205441)
24. Wiest PM, Flanigan T, Salata RA, et al. Serious infectious complications of corticosteroid therapy for COPD. Chest 1989; 95:1180-1184. (Pubitemid 19160135)
25. Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid- treated patients. Med Mycol 2009; 47 (Suppl 1):S271-S281.
26. Peter E, Bakri F, Ball DM, et al. Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis 2002; 35:e54-e56.
27. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis 2010; 23:145-151.
28. Greenberg SB. Infections in the immunocompromised rheumatologic patient. Crit Care Clin 2002; 18:931-956. (Pubitemid 35215569)
29. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
30. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004; 16:393-398. (Pubitemid 38803140)
31. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84:291-302. (Pubitemid 41368482)
32. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285-306. This is the most recent review on infectious complications associated with the use immunomodulating biologic therapies currently approved by the US Food and Drug Administration. It is a good summary about infectious complications from the first to the most innovative biologic therapies, when their use is quickly spreading.
33. Wallis RS, Schluger NW. Pulmonary infectious complications of tumor necrosis factor blockade. Infect Dis Clin North Am 2010; 24:681-692. This article focuses on recent studies that inform prevention and management of infections in the susceptible population on treatment with TNF blockers.
34. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2:602-610. (Pubitemid 44650948)
35. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20:443-449.
36. Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21:397-403.
37. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and antitumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556-1561.
38. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc 2008; 83:181-189.